Financial Performance - The company reported a basic earnings per share of 0.1300 yuan for 2024, an increase of 18.18% compared to 0.1100 yuan in 2023 [1] - Net profit for 2024 was 0.71 billion yuan, reflecting a 24.56% increase from 0.57 billion yuan in 2023 [1] - Operating revenue decreased to 20.49 billion yuan in 2024, down 12.47% from 23.41 billion yuan in 2023 [1] - The return on equity improved to 3.01% in 2024, up from 2.42% in 2023, marking a 24.38% increase [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 26,857.45 million shares, accounting for 50.3% of the circulating shares, with a decrease of 455.17 million shares compared to the previous period [1] - Guizhou Shenchu Holdings Group Co., Ltd. remains the largest shareholder with 9,066.16 million shares, representing 16.98% of total share capital [2] - Guizhou Maijisi Investment Management Co., Ltd. holds 8,800.19 million shares, accounting for 16.48% of total share capital, with no change [2] Dividend Distribution - The company announced a dividend distribution plan of 1.5 yuan per share (including tax) [3]

关于参加上海辖区上市公司 2024 年投资者网上集体 接待日暨中报业绩说明会的公告 | 证券代码：A | 股 600613 | 股票简称：A | 股 神奇制药 | 编号：2024-026 | | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 | B 股 | 上海神奇制药投资管理股份有限公司 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net/html/143790.shtml），或关注微信公众号：全景财经，或下 载全景路演 APP,参与本次互动交流，活动直播时间为 2024 年 9 月 13 日（周五） 14:00-16:30。届时公司高管将在线就公司 2024 年度中报业绩、公司治理、发展 战略、经营状况、融资计划、股权激励和可持续发展等投资者关心的问题，与投 资者进行沟通与交流；出席本次网上集体接待日的人员有：董事、总经理冯斌先 生，财务总监陈之勉先生、独立董事陈世贵先生和董事会秘书吴克兢先生。欢迎 广大投资者踊跃参与！ 特此公告。 上海神奇制药投资管理股份有限公司董事会 2024 年 9 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, with total revenue reaching RMB 500 million, representing a 20% year-over-year growth[8]. - The net profit for the first half of 2024 was RMB 100 million, an increase of 15% compared to the same period last year[8]. - User data indicates a growth in active users, with the number increasing to 1 million, up from 800,000 in the previous year, marking a 25% increase[8]. - The company's operating revenue for the first half of 2024 was approximately ¥1.11 billion, a decrease of 7.91% compared to the same period last year[15]. - Net profit attributable to shareholders increased by 8.93% to approximately ¥37.84 million, driven by profit growth in the pharmaceutical manufacturing sector[17]. - The net cash flow from operating activities decreased by 13.66% to approximately ¥122.91 million, primarily due to reduced cash inflow from sales[17]. - Basic and diluted earnings per share increased by 7.69% to ¥0.07, reflecting profit growth in the pharmaceutical manufacturing sector[16]. - The total profit for the first half of 2024 was CNY 47,318,177.33, down 11.8% from CNY 53,673,235.30 in the first half of 2023[76]. - The company achieved a net profit attributable to shareholders of CNY 37,837,024.85, an increase from CNY 34,735,718.51 in the first half of 2023[76]. Market Strategy and Expansion - The company plans to launch two new products in Q4 2024, aiming to capture a larger market share in the pharmaceutical sector[8]. - Future outlook suggests a projected revenue growth of 30% for the full year 2024, driven by new product launches and market expansion strategies[8]. - Market expansion efforts include entering three new provinces in China by the end of 2024, which is expected to increase market penetration by 15%[8]. - The company is actively expanding its marketing strategy to enhance brand awareness and optimize channel management, particularly in the OTC segment[24]. Research and Development - The company is investing RMB 50 million in R&D for new technologies aimed at improving production efficiency and product quality[8]. - R&D expenses have increased due to a focus on enhancing innovation capabilities and product upgrades, reflecting the company's commitment to deepening research in key therapeutic areas[25]. - Research and development expenses increased to CNY 25,115,733.73, up 18.5% from CNY 21,258,469.30 in the previous year[75]. Financial Health and Management - The company has maintained a strong balance sheet with a current ratio of 2.5, indicating good short-term financial health[8]. - The company has no plans for mergers or acquisitions in the near term, focusing instead on organic growth strategies[8]. - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[2]. - The company has established a robust internal control management system to enhance profitability and operational efficiency[26]. Quality Control and Compliance - The company has established a mature quality management system, with all subsidiaries having completed the new GMP/GSP certification[21]. - The company has maintained a 100% pass rate in quality inspections, implementing dynamic GMP management to enhance product safety and quality control[23]. - The company has implemented a quality management system to enhance product quality control, ensuring compliance with new regulations following the enforcement of the revised Drug Administration Law[45]. Environmental and Social Responsibility - The company is committed to strengthening its environmental protection measures in response to stricter regulations in the pharmaceutical industry[44]. - The company has established environmental protection management institutions across its facilities, employing dedicated personnel to oversee compliance with pollution control measures[50]. - The company has optimized its production processes to control pollutant emissions throughout the entire production cycle[51]. Shareholder and Equity Information - No profit distribution or capital reserve transfer is planned for the year, with no dividends or stock bonuses issued[48]. - The total amount of guarantees provided by the company, including those to subsidiaries, is 330 million RMB, which accounts for 13.84% of the company's net assets[60]. - As of the end of the reporting period, the total number of common shareholders is 57,323, with the largest shareholder holding 16.98% of the shares[63]. Asset Management - The company’s total assets at the end of the reporting period are CNY 2,362,023,019.81[92]. - The company’s total liabilities at the end of the reporting period are CNY 2,315,129,813.08[92]. - The company has not reported any significant changes in the status of temporarily idle fixed assets or those without property certificates[194]. Revenue Recognition and Accounting Policies - The company recognizes revenue when it fulfills performance obligations in contracts, measuring it based on the transaction price allocated to each performance obligation[148]. - The company recognizes revenue based on the progress of performance obligations, using either the output method or input method, depending on the nature of goods or services[149]. - The company recognizes investment income based on the cash dividends or profits declared by the invested entity, reflecting a conservative approach to income recognition[123].

Financial Performance - The company's operating revenue for 2023 was ¥2,340,945,518, a decrease of 2% compared to ¥2,388,617,677 in 2022[21]. - Net profit attributable to shareholders increased by 17.41% to ¥57,000,674.55 from ¥48,548,121.74 in the previous year[23]. - The basic and diluted earnings per share rose by 22.22% to ¥0.11, up from ¥0.09 in 2022[22]. - Cash flow from operating activities decreased by 32.47% to ¥215,590,355.95, down from ¥319,232,403.36 in 2022[21]. - Total assets decreased by 3.15% to ¥3,279,335,678.82 from ¥3,386,135,812.03 in 2022[21]. - The net assets attributable to shareholders increased slightly by 0.36% to ¥2,335,387,196.13 from ¥2,327,112,527.12 in 2022[21]. - The net profit after deducting non-recurring gains and losses increased by 0.84% to ¥49,103,973.11 from ¥48,693,784.94 in 2022[23]. - The total profit for 2023 was 83.41 million yuan, representing a year-on-year increase of 31.92%[32]. - The company reported a significant decline in cash inflow from sales, impacting the overall cash flow[23]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 1 RMB per 10 shares, totaling 53,407,162.8 RMB, based on a total share capital of 534,071,628 shares as of December 31, 2023[5]. - The company distributed a cash dividend of 1 RMB per 10 shares, totaling 53,407,162.80 RMB, which represents 93.70% of the net profit attributable to ordinary shareholders in the consolidated financial statements[193]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[4]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for providing guarantees[8]. - The company has confirmed that there are no instances where more than half of the directors cannot guarantee the authenticity, accuracy, and completeness of the annual report[9]. - The company has maintained a consistent financial reporting process, ensuring the accuracy and completeness of financial statements[5]. - The internal control audit report received a standard unqualified opinion[197]. - There were no significant deficiencies in internal control during the reporting period[197]. - The company has no reported risks or dissenting opinions from the supervisory board during the reporting period[183]. Risk Management - The company has detailed potential risks in the section discussing future development in the annual report[9]. - The company has a comprehensive risk management strategy outlined in the annual report[9]. - The company recognizes the high risks associated with new drug development, including long cycles and potential market acceptance issues, and will enhance feasibility studies before new drug projects[148]. - The company is facing risks from rising prices of raw materials, particularly traditional Chinese medicine, which could affect production costs and profitability[147]. - The company will continue to strengthen strategic reserves of key medicinal materials to alleviate cost increases from raw material price hikes[147]. Research and Development - The company continued to invest in R&D, achieving multiple technological innovations and quality standard improvements, with some results reaching a leading level in the country[40]. - The company has increased R&D investment in traditional Chinese medicine, achieving multiple technological innovations and quality standard improvements, with some results already applied in products and pending national patent applications[97]. - The company’s R&D projects are primarily in the basic research phase, focusing on various traditional Chinese medicine formulations[110]. - The company plans to improve its research and development management system and attract high-quality talent to accelerate the development process and increase the conversion rate of research outcomes[148]. - The company has established partnerships with several research institutions to enhance its research capabilities in the pharmaceutical field[107]. Market Strategy and Sales - The company has focused on optimizing its product structure and marketing strategies, leading to positive sales growth across prescription drugs, OTC products, and commercial products[37]. - The company has strengthened its commercial control and promotional strategies, enhancing its market coverage and improving sales efficiency[38]. - The company plans to enhance promotional efforts for cough and cold products to meet increasing market demand[81]. - The company aims to enhance its brand value and market influence, having received multiple awards in 2023, including "Top 100 Chinese Traditional Medicine Enterprises" and "Outstanding Brand Enterprise in Chinese Medicine" for its loquat cough series products[46][47]. - The company is actively working on enhancing the quality standards of traditional Chinese medicine and has made significant progress in the research and development of ethnic medicines[41]. Environmental Responsibility - The company has implemented a strict environmental responsibility system, including an "environmental veto" policy and enhanced self-inspection efforts across production bases to ensure compliance with environmental standards[150]. - The company invested 2.6165 million yuan in environmental protection during the reporting period[200]. - There were no administrative penalties related to environmental issues during the reporting period[200]. - The company adheres to various environmental discharge standards for air and water pollutants[200]. Governance and Management - The company has maintained a stable governance structure with independent operations of its board and supervisory committee[160]. - The total remuneration for the board of directors and senior management during the reporting period amounted to 206.6 million yuan[166]. - The company has established a performance-based compensation policy linking employee salaries to company and individual performance, with a focus on long-term development strategies[185]. - The company has a total of 10 independent directors, with some serving on multiple committees[181]. - The company has conducted a self-inspection regarding fund occupation and illegal guarantees, confirming no violations in transactions with its controlling shareholder[159]. Industry Trends - The pharmaceutical industry in China experienced a decline in overall growth, with the industrial added value of large-scale pharmaceutical enterprises approximately 1.3 trillion yuan, a year-on-year decrease of 5.2%[51]. - The revenue of pharmaceutical industrial enterprises reached 2.95525 trillion yuan, down 4% year-on-year, while profits fell to 412.72 billion yuan, a decrease of 16.2%[51]. - The Chinese pharmaceutical industry is projected to grow at a compound annual growth rate (CAGR) of 9.6% from 2020 to 2025[130]. - The company anticipates a decline in revenue and profit due to ongoing policy changes in the pharmaceutical industry, with a focus on adapting to these changes[143].

Financial Performance - The company's basic earnings per share for the first half of 2023 is CNY 0.065, an increase of 8.33% compared to CNY 0.060 in the same period last year[19]. - The diluted earnings per share for the same period is also CNY 0.065, reflecting the same growth rate of 8.33% year-on-year[19]. - The net profit margin, as indicated by the weighted average return on equity, increased to 1.47% from 1.36%, showing an improvement of 0.11 percentage points[19]. - The revenue for the reporting period increased by CNY 3.4286 million, representing a growth of 0.29%, primarily driven by sales growth in the pharmaceutical manufacturing sector[19]. - The basic earnings per share after deducting non-recurring gains and losses rose to CNY 0.061, marking a 10.90% increase from CNY 0.055 in the previous year[19]. - The net profit attributable to shareholders increased by CNY 2.76 million, a growth of 8.64% year-on-year, primarily due to profit growth in the pharmaceutical manufacturing sector[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by CNY 3.11 million, a growth of 10.53% year-on-year, mainly driven by profit growth in the pharmaceutical manufacturing sector[21]. - The total profit for the first half of 2023 is CNY 53,673,235.30, an increase from CNY 47,884,001.34 in the same period of 2022, representing a growth of approximately 3.7%[98]. - The net profit for the first half of 2023 is CNY 34,508,619.61, compared to CNY 32,762,295.91 in the first half of 2022, reflecting an increase of about 5.3%[98]. - The net profit attributable to shareholders of the parent company is CNY 34,735,718.51, up from CNY 31,972,949.32, indicating a growth of approximately 8.6%[98]. Revenue and Costs - The total revenue for the reporting period was CNY 1,205.68 million, a slight increase of 0.29% compared to the same period last year[21]. - The pharmaceutical manufacturing revenue was CNY 764.83 million, accounting for 63.44% of total revenue[30]. - The pharmaceutical commercial revenue was CNY 440.85 million, accounting for 36.56% of total revenue[31]. - The operating cost for the current period is approximately ¥568.5 million, reflecting an increase of 1.68% from ¥559.1 million in the previous year[40]. - Total operating costs decreased to ¥1,148,624,617.28 from ¥1,157,009,344.15, indicating a reduction of about 0.7% year-over-year[97]. Cash Flow and Assets - The net cash flow from operating activities increased by CNY 31.76 million, a growth of 28.72% year-on-year, mainly due to a reduction in procurement payments and expenses during the period[21]. - Cash and cash equivalents increased to ¥717.24 million, representing 21.98% of total assets, up from 19.42% in the previous period, a growth of 9.25%[41]. - The total assets amounted to ¥3,263,729,885.81, a decrease from ¥3,381,085,508.75 at the end of 2022, reflecting a decline of approximately 3.48%[90]. - The company's cash and cash equivalents increased to ¥64,177,960.19 from ¥38,816,976.95, marking a growth of approximately 65.2%[94]. - The total current liabilities decreased to ¥677,584,907.75 from ¥774,341,911.79, a reduction of about 12.48%[91]. Research and Development - Research and development expenses increased by 18.14% to approximately ¥21.3 million, up from ¥18 million in the previous year, indicating a focus on innovation[40]. - Research and development expenses for the first half of 2023 were ¥21,258,469.30, up from ¥17,994,239.54, indicating an increase of approximately 18.9%[97]. - The company is actively collaborating with research institutions to develop new products and improve its product pipeline[36]. Risk Management - The company emphasizes the importance of risk awareness regarding its future plans and development strategies[4]. - The company faces risks from dynamic adjustments in the National Medical Insurance catalog, which significantly impact revenue and profit based on whether drugs are included in the catalog and their bidding prices[52]. - Rising raw material costs due to stricter production standards and environmental regulations pose a risk to the company's profit margins, as price increases cannot be passed on to consumers[53]. - The company is implementing a dynamic early warning mechanism for policy changes in the pharmaceutical industry to adapt to regulatory shifts and enhance profitability[50]. Corporate Governance - There are no plans for profit distribution or capital reserve conversion into share capital during this reporting period[4]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[5]. - The report indicates that there are no violations of decision-making procedures regarding external guarantees[5]. - The company conducted a board and supervisory committee election on May 19, 2023, following the expiration of the current term[63]. - There were changes in senior management, including the appointment of a new financial director and board secretary[62]. Environmental and Compliance - The company has implemented a strict environmental protection policy, including a "one-vote veto" system for environmental compliance in production operations[57]. - The company has established environmental protection management institutions at all factories and has implemented measures to handle pollutants[68]. - The company has not disclosed any environmental penalties during the reporting period[67]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 64,869[82]. - The largest shareholder, Guizhou Magic Holdings (Group) Co., Ltd., holds 120,661,620 shares, representing 22.59% of the total shares[84]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters to drive future growth[97]. - The management provided guidance for the next quarter, anticipating a gradual recovery in revenue growth driven by new product launches and market expansion efforts[128].

Financial Performance - The company's operating revenue for 2022 was ¥2,388,617,677.74, representing a 3.72% increase compared to ¥2,303,032,719.00 in 2021[20]. - The net profit attributable to shareholders decreased by 30.37% to ¥48,477,141.78 from ¥69,622,537.91 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 25.90% to ¥48,622,804.98, compared to ¥38,620,695.82 in 2021[20]. - The net cash flow from operating activities increased by 73.25% to ¥319,232,403.36, up from ¥184,263,469.22 in 2021[20]. - Basic and diluted earnings per share decreased by 30.77% to ¥0.09 from ¥0.13 in the previous year[21]. - The weighted average return on equity decreased by 0.94 percentage points to 2.07% compared to 3.01% in 2021[21]. - The total assets at the end of 2022 were ¥3,381,085,508.75, reflecting a 7.37% increase from ¥3,148,970,121.43 in 2021[20]. - The net profit attributable to shareholders was 4,847.71 million yuan, a decrease of 30.37% compared to the previous year[32]. - The total assets at the end of 2022 amounted to 338,108.55 million yuan, with net assets of 232,744.99 million yuan, a decline of 0.72% year-on-year[33]. Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares, totaling 53,407,162.8 RMB based on a total share capital of 534,071,628 shares as of December 31, 2022[6]. - The company implemented a cash dividend policy, distributing CNY 1 per 10 shares, totaling CNY 53,407,162.80, which represents 76.71% of the net profit attributable to ordinary shareholders[184]. - The net profit attributable to ordinary shareholders for the year was CNY 69,622,537.91[184]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The company is committed to ensuring the authenticity, accuracy, and completeness of the annual report[4]. - The company has conducted self-inspections regarding fund occupation and illegal guarantees, finding no violations[154]. - There were no significant deficiencies in internal control during the reporting period[188]. - The company has not received a "non-standard opinion audit report" from its accounting firm[200]. Risk Management - The company has detailed potential risks in the section "Discussion and Analysis of Future Development" of the annual report[8]. - The company faces risks from policy changes and intensified competition in the pharmaceutical industry, particularly due to centralized procurement and price pressures[138]. - The company has established a dynamic warning mechanism to monitor policy changes and adapt its business strategies accordingly to maintain steady growth[139]. - Rising raw material costs due to stricter production standards and environmental regulations pose a risk to profit margins, as companies cannot pass these costs onto consumers[143]. - Drug development involves high costs and risks, with potential uncertainties affecting expected outcomes[144]. - Stricter environmental protection policies will increase compliance costs for pharmaceutical manufacturers, impacting profitability[145]. - The company is committed to improving its environmental management and compliance with regulations to mitigate risks associated with environmental standards[147]. Research and Development - Continuous investment in R&D led to advancements in various product lines, including anti-tumor, cardiovascular, and pediatric products, with some research outcomes reaching domestic leading levels[36]. - The company is actively exploring the innovation and development of traditional Chinese medicine, focusing on the registration and industrialization of classic formulas[36]. - The company has made significant progress in the industrialization of potential products, achieving breakthroughs in sales and quality standards[37]. - The company has established a comprehensive quality assurance system, continuously updating and improving its quality management practices[40]. - The company holds a total of 120 patents, including 69 invention patents, ensuring a strong intellectual property position[64]. - The R&D team consists of 303 personnel, with over 46% holding degrees above bachelor's level, indicating a strong technical foundation[101]. - The company collaborates with research institutions such as Guizhou University of Traditional Chinese Medicine to enhance its R&D capabilities[101]. - The company's R&D investment amounted to 106,462.40 million RMB, representing 1.93% of operating revenue and 1.94% of net assets, with a capitalization ratio of 0%[107]. Market and Sales Strategy - The company is committed to ensuring the safety and efficacy of its products through ongoing post-marketing studies and quality improvements[91]. - The company aims to enhance its oncology product line and maintain its leading position in the sodium cantharidate series of anti-tumor products through systematic development and new indication research[131]. - The company plans to increase R&D investment and collaborate with research institutions to develop chemical drugs, traditional Chinese medicine, and health products, following a "one product, one strategy" approach[132]. - The company is focusing on improving product quality standards and developing potential products, targeting a new profit growth point with苗药 (Miao medicine) varieties[132]. - The company is expanding its market share in the health sector, leveraging the "Healthy China" strategy and enhancing the sales of potential products like杜仲双降袋泡剂 (Du Zhong Double Reduction Granules) and维E三油胶丸 (Vitamin E Three Oil Capsules)[133]. - The company is enhancing its internal control systems to mitigate operational risks and improve efficiency, especially in light of increasing regulatory pressures in the pharmaceutical industry[135]. Corporate Governance - The company has a board of directors consisting of 9 members, including 3 independent directors, meeting the requirement of one-third independent representation[153]. - The company has established a performance evaluation standard and procedure for senior management to ensure accountability[154]. - The controlling shareholder, Shenqi Holdings, has not interfered with the company's operations, maintaining independence in assets, business, and finance[156]. - The company has implemented a comprehensive information disclosure management system to ensure transparency and protect shareholder rights[154]. - The company has established specialized committees under the board, including strategy and investment, audit, and remuneration committees, to enhance governance[153]. - The company respects the rights of stakeholders, including creditors and employees, fostering collaborative development[154]. - The company has adhered to the latest corporate governance requirements set by regulatory authorities, continuously improving its governance structure[152]. Employee Management - The total number of employees in the parent company is 6, while the main subsidiaries employ 1,564, resulting in a total of 1,570 employees[176]. - The company has established a salary policy that links employee compensation to company and individual performance, with a focus on long-term development strategies[178]. - The company plans to conduct various training programs, including legal, ethical, and product knowledge training, to enhance employee skills and overall management levels[179]. - The company has a structured approach to employee training, focusing on both internal and external training methods to improve overall employee quality[179]. Environmental Responsibility - The company invested CNY 3.83 million in environmental protection measures during the reporting period[192]. - The company has set up an environmental protection management organization and implemented measures to control pollutant emissions[193]. - The company did not disclose any social responsibility or ESG reports during the reporting period[195].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 582,797,540.36, representing a decrease of 0.93% compared to the same period last year[7] - The net profit attributable to shareholders was CNY 23,790,846.61, reflecting an increase of 1.39% year-on-year[7] - Total operating revenue for Q1 2023 was ¥582,797,540.36, a decrease of 0.76% compared to ¥588,244,525.86 in Q1 2022[20] - Net profit for Q1 2023 was ¥23,351,102.30, representing a 12.5% increase from ¥20,747,533.82 in Q1 2022[20] - The net profit attributable to the parent company's shareholders for Q1 2023 was ¥23,790,846.61, an increase from ¥23,465,067.59 in Q1 2022, representing a growth of approximately 1.38%[22] - The total comprehensive income for Q1 2023 was ¥25,338,281.91, compared to ¥15,936,326.21 in Q1 2022, indicating a significant increase of approximately 58.73%[22] Cash Flow and Investments - The net cash flow from operating activities decreased significantly by 62.61%, amounting to CNY 23,483,555.88[11] - Operating cash flow for Q1 2023 was ¥23,483,555.88, down from ¥62,803,872.32 in Q1 2022, reflecting a decrease of approximately 62.66%[24] - The company incurred a net cash outflow from investing activities of ¥23,573,667.45 in Q1 2023, compared to a smaller outflow of ¥5,654,225.83 in Q1 2022, indicating a significant increase in investment expenditures[25] - The net cash outflow from financing activities was ¥8,231,985.32 in Q1 2023, an improvement from a larger outflow of ¥17,774,068.93 in Q1 2022, suggesting better management of financing costs[25] - The company received cash from borrowings amounting to ¥15,857,135.99 in Q1 2023, while cash outflows for debt repayment were ¥17,000,000.00, indicating a net cash outflow in financing activities[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,175,677,192.50, down 6.08% from the end of the previous year[7] - Total assets as of March 31, 2023, were ¥3,175,677,192.50, a decrease from ¥3,381,085,508.75 at the end of 2022[17] - Total liabilities decreased to ¥777,162,407.62 from ¥1,007,909,005.78 at the end of 2022, reflecting a reduction of approximately 22.8%[18] - Cash and cash equivalents amounted to ¥646,278,357.71, slightly down from ¥656,490,488.19 at the end of 2022[16] - Cash and cash equivalents at the end of Q1 2023 stood at ¥646,243,324.02, compared to ¥533,117,647.86 at the end of Q1 2022, showing an increase of approximately 21.18%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 72,288[12] - The top shareholder, Guizhou Magic Holdings Group, holds 22.59% of the shares, with 120,661,620 shares pledged[13] Research and Development - Research and development expenses increased by 215.75%, indicating a significant rise in investment in innovation[10] - Research and development expenses increased significantly to ¥19,160,727.57, up 215.5% from ¥6,068,230.05 in Q1 2022[20] Other Financial Metrics - The company reported a weighted average return on equity of 1.02%, which is a slight increase of 0.02% compared to the previous year[7] - The company experienced a 51.68% decrease in receivables financing due to the maturity of previously endorsed notes[10] - The company did not report any investment income for the period, marking a 100% decrease in this category[10] - Accounts receivable increased to ¥412,635,503.53 from ¥361,049,109.95, marking a rise of 14.3%[16] - Inventory decreased to ¥202,204,352.43 from ¥218,822,277.02, a decline of 7.6%[16] - Shareholders' equity totaled ¥2,398,514,784.88, up from ¥2,373,176,502.97 at the end of 2022, indicating a growth of 1.06%[18] - The other comprehensive income after tax for Q1 2023 was ¥1,987,179.61, a recovery from a loss of ¥7,688,207.61 in Q1 2022, reflecting a positive turnaround in financial performance[22] - Basic and diluted earnings per share remained stable at ¥0.04 for both Q1 2023 and Q1 2022, indicating consistent profitability on a per-share basis[22]

| 证券代码：A | 股 600613 | 股票简称：A | 股 神奇制药 | | 编号：2023-017 | | --- | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 B | 股 | | 届时公司的董事总经理冯斌先生、独立董事陈世贵先生、财务总监李发淼先 生和董事会秘书吴克兢先生将通过网络在线交流形式与投资者就公司治理、发展 战略、经营状况、融资计划、股权激励和可持续发展等投资者关注的问题进行沟 通。 欢迎广大投资者积极参与。 特此公告。 上海神奇制药投资管理股份有限公司 关于参加 2023 年上海辖区上市公司年报集体业绩说 明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●会议召开时间： 2023 年 5 月 10 日（周三）15:00 至 17:00 ●会议召开方式：上证路演中心网络互动 ● 会议召开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sse ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,202,246,417.57, representing a 4.03% increase compared to CNY 1,155,688,396.85 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 27.94% to CNY 31,972,949.32 from CNY 44,371,523.59 year-on-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 29,562,868.02, down 35.28% from CNY 45,681,482.77 in the previous year[19]. - The company's basic and diluted earnings per share decreased by 25.00% to CNY 0.06 compared to the same period last year[20]. - The net profit attributable to shareholders decreased by 27.94%, amounting to CNY 3,199.86 million, primarily due to increased sales costs and financial expenses in the pharmaceutical manufacturing sector[21]. - The total comprehensive income for the first half of 2022 was ¥24,133,989.75, down from ¥37,793,885.71 in the first half of 2021, indicating a decrease of about 36%[117]. Cash Flow and Assets - The net cash flow from operating activities increased by 31.78% to CNY 110,589,966.04 compared to CNY 83,918,218.30 in the same period last year[19]. - Cash and cash equivalents at the end of the period amounted to ¥539,909,211.47, representing 16.84% of total assets, an increase of 9.34% compared to the previous year[47]. - The net cash flow from investing activities increased by 77.77% primarily due to decreased cash expenditures for fixed asset purchases[46]. - The total assets at the end of the reporting period were CNY 3,205,457,500.09, reflecting a 1.79% increase from CNY 3,148,970,121.43 at the end of the previous year[19]. - The total current liabilities were RMB 534,415,700.63, compared to RMB 479,805,740.28 at the beginning of the period, marking an increase of about 11.4%[110]. Operating Costs and Expenses - Operating costs rose by 15.28% to approximately ¥559 million, primarily due to the depreciation from the new production base and rising raw material prices[45]. - Financial expenses surged by 326.77% to approximately ¥6.55 million, attributed to interest from project financing after the completion of the Shawan project[45]. - Management expenses were reduced by 5.00% to approximately ¥42.85 million due to enhanced cost control measures[45]. - The company reported a decrease in management expenses from ¥3,772,770.40 in the first half of 2021 to ¥2,962,551.57 in the first half of 2022, a reduction of approximately 21%[120]. Market and Industry Trends - The total revenue for the pharmaceutical manufacturing industry in China decreased by 0.6% year-on-year, totaling CNY 1,400.78 billion in the first half of 2022[26]. - The average annual growth rate for the retail pharmacy OTC market is expected to reach 4-6%, significantly higher than the 2-3% growth rate for public hospitals[27]. - The government plans to expand the scope of centralized procurement, which will continue to exert pressure on traditional generic drug and medical device companies[30]. - The company faces risks from policy changes in the pharmaceutical industry, including price reductions and increased regulatory scrutiny, which could impact production costs and profitability[56]. Risks and Challenges - The ongoing COVID-19 pandemic poses risks to product sales due to potential lockdowns and reduced hospital visits, affecting overall market demand[58]. - Rising raw material costs due to stricter production standards and potential supply chain disruptions could pressure the company's profit margins[61]. - The risk of unmet expectations in drug research and development could lead to financial losses if new products fail to gain regulatory approval or achieve anticipated sales[64]. - The company is facing stricter environmental protection requirements due to new policies and regulations, which may increase expenditures on environmental facilities and impact profitability[65]. Environmental Responsibility - The company operates a wastewater treatment station and online monitoring system, ensuring compliance with environmental standards[77]. - The company has implemented measures to reduce carbon emissions by ensuring proper disposal and recycling of hazardous and general solid waste[85]. - The company has established a rigorous quality control system, with no reported product quality incidents to date, but acknowledges potential risks in downstream logistics[67]. - The company has committed to maintaining the independence of its operations and reducing related party transactions[88]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 46,912[100]. - The largest shareholder, Guizhou Shenqi Investment Co., Ltd., holds 24.59% of the shares, totaling 131,301,620 shares[102]. - The company has not proposed any profit distribution plan or capital reserve transfer to increase share capital during the reporting period[5]. - There are no proposed profit distributions or capital reserve transfers for the half-year period, indicating a focus on reinvestment[73].

Financial Performance - In 2021, the company's operating revenue reached CNY 2,303,032,719, representing a 26.61% increase compared to CNY 1,819,006,691 in 2020[19] - The net profit attributable to shareholders was CNY 69,622,537.91, a significant turnaround from a loss of CNY 341,202,593.32 in the previous year, marking a 120.41% increase[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 38,620,695.82, improving by 111.21% from a loss of CNY 344,510,890.04 in 2020[19] - The net cash flow from operating activities was CNY 184,263,469.22, an 85.94% increase from CNY 99,097,235.25 in 2020[19] - Basic earnings per share rose to CNY 0.13, reflecting a growth of 120.31% year-on-year[30] - The weighted average return on equity increased by 20.88 percentage points to 3.01%[22] - The company achieved dual growth in OTC and prescription drug sales by optimizing channel management and enhancing market coverage, with a focus on academic promotion and brand awareness[33] Assets and Investments - As of the end of 2021, the total assets amounted to CNY 3,148,970,121.43, reflecting a 1.65% increase from CNY 3,097,971,351.94 at the end of 2020[19] - The net assets attributable to shareholders were CNY 2,344,283,894.81, a 2.94% increase from CNY 2,277,367,601.10 in 2020[19] - The company disposed of investment subsidiaries, resulting in investment income of over CNY 28.1 million during the reporting period[22] - The company’s long-term equity investments increased by 23.28% to 3.30 million yuan, reflecting positive investment performance[105] Research and Development - Research and development expenses rose to CNY 50.95 million, reflecting a 19.06% increase from the previous year[83] - The company has a total of 133 patents, including 84 invention patents, enhancing its market competitiveness[80] - The company is conducting ongoing research on the safety and quality standards of its products, including sodium cantharidinate for liver cancer treatment[122] - The company has established partnerships with several universities and research institutions to enhance its R&D capabilities[121] Market Strategy and Operations - The company emphasizes innovation in its R&D strategy, focusing on upgrading existing products and enhancing its competitive edge in the industry[72] - The company is focusing on the integration of traditional Chinese medicine and Western medicine as a key strategy for future development in pandemic prevention and treatment[52] - The company plans to establish an OTC marketing management center, aiming to build a team of approximately 500 people by the end of 2022 to enhance terminal promotion services[145] - The company will implement a dynamic price warning mechanism for bulk raw materials to manage procurement costs effectively amid rising raw material prices[153] Industry Trends and Challenges - The COVID-19 pandemic has led to a surge in demand for vaccines and testing products, contributing to the rapid growth of related companies[48] - The regulatory environment for the pharmaceutical industry has become more stringent, with new policies aimed at enhancing drug quality and innovation efficiency[53] - The ongoing pandemic has created fluctuations in healthcare demand, impacting the production activities of pharmaceutical manufacturers[48] - The chemical drug sector faced pressure from centralized procurement policies and a decline in hospital admissions, leading to a slower overall growth rate[113] Corporate Governance and Compliance - The company has taken measures to ensure compliance with the latest corporate governance regulations[169] - The board of directors consists of 9 members, including 3 independent directors, meeting the legal requirements[170] - The company has implemented a performance evaluation standard for senior management to ensure accountability[171] - The company has conducted a self-inspection regarding fund occupation and illegal guarantees, finding no issues[171] Employee and Organizational Structure - The total number of employees in the parent company is 7, while the main subsidiaries employ 1,364, resulting in a total of 1,371 employees[194] - The company has established a salary policy that links employee compensation to company performance and individual performance, with salaries consisting of base pay, position pay, and performance pay[195] - The company emphasizes targeted training programs for different employee categories, including management, technical staff, and frontline workers, to enhance overall employee quality and management levels[197] Future Outlook - The company has set a revenue guidance for 2022, projecting a growth rate of 10% to 12%[183] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[181] - In 2022, the company aims to enhance R&D and innovation capabilities, focusing on core products in oncology and cardiovascular sectors, with increased investment in R&D and collaboration with domestic and international research institutions[144]